The i-Technology Media!
Register | Log in
   
 
.NET  ·  AJAX  ·  CLOUD  ·  ECLIPSE  ·  FLEX  ·  OPEN WEB  ·  iPHONE  ·  JAVA  ·  LINUX  ·  OPEN SOURCE  ·  ORACLE  ·  PBDJ  ·  SEARCH  ·  SILVERLIGHT  ·  SOA  ·  VIRTUALIZATION  ·  WEB 2.0  ·  WIRELESS  ·  XML
Comments
Improving the Efficiency of SOA-Based Applications
jhv1blz5 wrote: The article validated SOA as an IT architecture paradigm that can be leveraged in many ways. Taking data storage, scalability and application performance to a nifty level using SOA Application Grid infrastructure will no doubt enhance data and application performance on Oracle architecture platforms, it also has the promise of a cost effective and efficient IT delivery model. The very benefits of SOA.
Jul. 3, 2009 10:31 AM EDT
Cloud Computing | Virtualization
November 2 - 4
Register Today and SAVE !..
Did you read today's front page stories & breaking news?
Live Google News by SYS-CON!

Top Three Links You Must Click On


From the Wires
Serenex Announces Issuance of European Patent for Oral Mucositis Product SNX-1012
Serenex Announces Issuance of European Patent for Oral Mucositis Product SNX-1012

By: Marketwire .
Mar. 20, 2007 01:00 PM

DURHAM, NC -- (MARKET WIRE) -- 03/20/07 -- Serenex, Inc., an integrated oncology-focused drug discovery and development company, announced today the issuance of a patent covering methods of treating or preventing mucositis by the European Patent Office ("EPO"). The patent, EP 212050B1, covers a broad class of compounds in various formulations that may treat mucositis of multiple mucosal surfaces.

"We are pleased to have been awarded this patent from the EPO. The patent significantly strengthens our intellectual property estate surrounding SNX-1012 which now includes IP protection in both the U.S. and Europe," said Richard Kent, M.D., president and chief executive officer of Serenex. "The issuance of this patent is another important step toward the commercialization of SNX-1012, which we believe is a best in class product that will bring relief to cancer patients suffering from oral mucositis."

Oral mucositis results in inflammation and ulceration of the mouth and throat tissue lining and is the most common debilitating toxicity induced by chemotherapy and radiation therapy regimens. In severe cases oral mucositis can lead to patients requiring total parenteral nutrition, IV narcotic analgesics to control pain, and hospitalization. A serious consequence of oral mucositis is that it frequently leads to the interruption of radiation or chemotherapeutic treatment, which results in an undesirable decrease in efficacy. There are no approved therapeutic agents for the prevention or treatment of oral mucositis in solid tumor patients receiving radiation or chemotherapy and yet these patients represent approximately 90% of all oral mucositis cases. The size of this market in the U.S. is estimated to be more than $1 billion.

SNX-1012 targets multiple inflammatory and other key pathways involved in the pathophysiology of oral mucositis. The product is administered as a topical, transmucosal agent in the form of an oral rinse that interferes with many of the biological targets necessary for mucositis development. Four phase 1 trials have been successfully completed, including a phase 1b study at the Fred Hutchinson Cancer Center in Seattle, which showed strong indications of pharmacological activity and an excellent safety profile. The product is currently in a phase 2 trial comparing multiple doses of SNX-1012 against placebo control.

About Serenex

Serenex is an integrated oncology-focused drug discovery and development company. Serenex's lead program, SNX-1012, a product for chemotherapy and radiation-induced oral mucositis in solid tumor patients, is scheduled to complete phase 2 clinical trials in early 2008. Oral mucositis, which represents a large and underserved market, frequently causes clinicians to interrupt therapy which directly leads to decreased rates of efficacy. Additionally, Serenex has a novel small molecule inhibitor of Heat Shock Protein 90 (Hsp90) which is scheduled to begin clinical trials in May 2007. Hsp90 is a central protein responsible for chaperoning a large number of oncogenic proteins (such as Her2 and Raf) that are necessary to support cancer cell survival and growth. Serenex's pipeline is powered by a proprietary high throughput screening platform which enables the company to profile compounds, en masse, against thousands of important therapeutic and toxicity targets. Website: www.serenex.com.


CONTACT:

Ian Howes
CFO & Sr. V.P. Corporate Development
Serenex, Inc.
919/281-6031
Email Contact

Michelle Linn
Linnden Communications
508/419-1555
Email Contact

Published Mar. 20, 2007
Copyright © 2007 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.
About Marketwire .
Copyright © 2009 Marketwire. All rights reserved. All the news releases provided by Market Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021

SYS-CON Featured Whitepapers
ADS BY GOOGLE
Breaking Java News
VASCO to Release Q2 2009 Results on July 23, 2009
Leading International Climate Scientists Call on World Leaders for Global Emissions Peak by 2020
Leading Online Casino Announces VIP Award Scheme
New From Babylon - Free Upgrade for All Mac Users - The Improved Babylon for Mac Now With Online and Offline Dictionaries
New From Babylon - Free Upgrade for All Mac Users - The Improved Babylon for Mac Now With Online and Offline Dictionaries
New Alfresco Release Cuts Cost of Records, Email, Mobility, Extranets and CMIS Support

ADVERTISE   |   MAGAZINE SUBSCRIPTIONS   |   FREE BREAKING-NEWSLETTERS!   |   SYS-CON.TV   |   BLOG-N-PLAY!   |   WEBCAST   |   EDUCATION   |   RESEARCH

.NET Developer's Journal - .NETDJ   |   ColdFusion Developer's Journal - CFDJ   |   Eclipse Developer's Journal - EDJ   |   Enterprise Open Source Magazine - EOS
Open Web Developer's Journal - OPENWEB   |   iPhone Developer's Journal - iPHONE   |   Virtualization - Virtualization   |   Java Developer's Journal - JDJ   |   Linux.SYS-CON.com
PowerBuilder Developer's Journal - PBDJ   |   SEO / SEM Journal - SJ   |   SOAWorld Magazine - SOAWM   |   IT Solutions Guide - ITSG   |   Symbian Developer's Journal - SDJ
WebLogic Developer's Journal - WLDJ   |   WebSphere Journal - WJ   |   Wireless Business & Technology - WBT   |   XML-Journal - XMLJ   |   Internet Video - iTV
Flex Developer's Journal - Flex   |   AJAXWorld Magazine - AWM   |   Silverlight Developer's Journal - SLDJ   |   PHP.SYS-CON.com   |   Web 2.0 Journal - WEB2
Apache   |   CMS   |   CRM   |   HP   |   Oracle Journal   |   Perl   |   Python   |   Red Hat   |   Ruby on Rails   |   SAP   |   SaaS

SYS-CON MEDIA:   ABOUT US   |   CONTACT US   |   COMPANY NEWS   |   CAREERS   |   SITE MAP
SYS-CON EVENTS:   |  AJAXWorld Conference & Expo  |  iPhone Developer Summit  |  Cloud Computing Conference & Expo  |  SOA World Conference & Expo  |  Virtualization Conference & Expo
INTERNATIONAL SITES:   India  |  U.K.  |  Canada  |  Germany  |  France  |  Australia  |  Italy  |  Spain  |  Netherlands  |  Brazil  |  Belgium
 Terms of Use & Our Privacy Statement     About Newsfeeds / Video Feeds
Copyright ©1994-2008 SYS-CON Publications, Inc. All Rights Reserved. All marks are trademarks of SYS-CON Media.
Reproduction in whole or in part in any form or medium without express written permission of SYS-CON Publications, Inc. is prohibited.
 
close this window